INDVIndivior Pharmaceuticals, Inc.
Is it safe?
One accounting flag to check: a safe balance sheet and comfortable debt (AA), but an accounting pattern worth a look (common in fast growers) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Several accounting flags in the manipulation-likely range Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Insiders were net sellers (-$657K, 90 days to Oct 8, 2026), selling is often routine.
Rock-solid balance sheet, low leverage. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -94% · now 14% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can INDV take a bad year?
Indivior Pharmaceuticals, Inc. carries $265M of net debt at 0.62× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.62×
Net debt / EBITDA · −0.79× a year ago · the load is going up
- Altman Z-score
- 3.46
Altman Z-score · safe zone, above 3
- Cash runway
- 2.0 years
Cash runway · burning $28M a quarter at the current rate
Details›
- Total debtQ2 2026
- $487M
- Cash and short-term investments
- $222M
- Net debt
- $265M
- EBITDA, trailing twelve months
- $430M
- Operating profit, trailing twelve months
- $421M
- Total debt / EBITDA
- 1.13×
- Annualised volatilitytwo years of daily moves
- 48%
- Worst drawdown on file
- −94%
- Below its 52-week high
- 14%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 41 by RyuScore